Prognostic role of HER2-low expression in HR +/HER2- metastatic breast cancer treated with CDK4/6 inhibitors
The low expression of human epidermal growth factor receptor 2 (HER2) in hormone receptor positive (HR +) metastatic breast cancer has become a novel area of interest, particularly after the demonstration that it can be targeted with antibody–drug conjugates (ADCs). This study aimed to describe the clinicopathological...